THERAVECTYS Provides Update on Its Phase I/II Lentiviral Vector-Based Therapeutic Vaccine Trial

November 18, 2014 THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapies, reports promising preliminary results in the first-ever vaccination trial conducted with lentiviral vectors. The randomized, placebo-controlled trial currently enrolls 38 HIV-positive patients under highly active antiretroviral therapy (HAART) in 12 clinical sites in France and Belgium andĀ aims at comparing …